Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466785 | 0.88 | DRD2 (0.51) | DRD2PNMTPHGDHKMT2AACACB | |
| SCHEMBL21882783 | 0.87 | DRD2 (0.42) | DRD2PNMTLMNAKMT2ADRD3 | |
| SCHEMBL4382315 | 0.83 | DRD2 (0.50) | DRD2PNMTACACBHRH3 | |
| SCHEMBL19962315 | 0.83 | DRD2 (0.49) | DRD2PHGDHKMT2AACACBC5AR1 | |
| SCHEMBL12852534 | 0.80 | MAOA (0.52) | DRD2SIGMAR1PHGDHDRD4DRD3 | |
| SCHEMBL3423587 | 0.80 | DRD2 (0.47) | DRD2PHGDHKMT2AACACB | |
| SCHEMBL14904892 | 0.79 | PNMT (0.57) | DRD2PNMTSIGMAR1KMT2ADRD4 | |
| SCHEMBL16154958 | 0.75 | PNMT (0.54) | DRD2PNMTSIGMAR1KMT2ADRD4 | |
| SCHEMBL17124796 | 0.75 | PHGDH (0.44) | DRD2PHGDHKMT2AACACBC5AR1 | |
| SCHEMBL22597699 | 0.75 | PNMT (0.51) | DRD2PNMTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | OPRM1, OPRL1, OPRD1 | DRD2 179/4885PNMT 433/4885SIGMAR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.